August 4, 2016
Takeda Pharmaceutical’s once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor Zafatek (trelagliptin) left the strongest impression on GPs in June through a series of promotional channels, including drug reps and seminars, a monthly survey showed. According to the survey conducted by Anterio, Zafatek...read more